课题基金 / 基金详情

Targeting multiple signaling pathways for tinnitus prevention and treatment

Targeting multiple signaling pathways for tinnitus prevention and treatment
针对耳鸣预防和治疗的多个信号通路
批准号:
10010292
负责人:
Jianxin Bao
金额:
$97.26万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2022-06-30

项目摘要

项目成果

Jianxin Bao的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Subjective tinnitus is the perception of a phantom sound, which negatively impacts the quality of life for millions of people worldwide. Despite the great demand for remedy, there are no FDA-approved drugs to prevent or treat tinnitus. Possible causes of tinnitus are complicated. The current view is that hyperactivity in the central auditory nervous system contributes to the majority of tinnitus cases. This abnormal electrical activity, including an increase in delta-band activity, may be the direct result of an increase in T-type calcium channel activity. Other studies suggest that inflammatory responses within the brain may be involved in the development and persistence of tinnitus; therefore, drug candidates targeting both inflammatory and calcium signaling pathways may act synergistically to prevent and treat tinnitus. Tetrandrine (TET), an approved drug used in China, exhibits both anti-inflammatory and calcium channel-blocking properties. Using a new tinnitus detection method in mice, we have shown that both salicylate-induced and noise-induced tinnitus can be effectively treated by TET in a dose-dependent manner. Our hypothesis is that TET or its chemical analogs can be developed as drugs to prevent and treat tinnitus. In our proposed experiments, we have two parallel goals: (1) obtain investigational new drug (IND)-enabling toxicity and pharmacokinetics data for TET (Aim 1) and (2) optimize second-generation products with structure-activity relationship studies of TET and its chemical analogs (Aim 2). Successful accomplishment of Aim 1 will enable TET to advance into clinical development. In addition, the studies of Aim 2 will enable us to identify additional candidates in case TET fails at clinical stages. By targeting multiple cellular signaling pathways that impinge upon tinnitus, our study will open new areas for the treatment and prevention of tinnitus. The extensive body of data publicly available for TET and its analogs will help us significantly reduce development time and costs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting multiple signaling pathways for tinnitus prevention and treatment
  • 批准号:
    10197878
  • 项目类别:
  • 资助金额:
    $120.73万
  • 财政年份:
    2020
  • 负责人:
    Jianxin Bao
  • 依托单位:
An unique patient population for clinical trials against noise-induced hearing loss
  • 批准号:
    10006932
  • 项目类别:
  • 资助金额:
    $9.99万
  • 财政年份:
    2018
  • 负责人:
    Jianxin Bao
  • 依托单位:
Develop a new cisplatin-based drug combination with reduced ototoxicity
  • 批准号:
    9408928
  • 项目类别:
  • 资助金额:
    $22.47万
  • 财政年份:
    2017
  • 负责人:
    Jianxin Bao
  • 依托单位:
Developing a Nutraceutical Product against Noise-Induce Hearing Loss
  • 批准号:
    9459236
  • 项目类别:
  • 资助金额:
    $22.47万
  • 财政年份:
    2017
  • 负责人:
    Jianxin Bao
  • 依托单位:
海外基金